Investor Relations

News Release

PPD Honored for Employee Development Programs that Deliver Results for Customers

Training magazine recognizes PPD for innovative training practices for 10th consecutive year

WILMINGTON, N.C. (Feb. 17, 2021) – PPD, Inc. (Nasdaq: PPD) has been recognized for the 10th consecutive year as one of the leading U.S. businesses for employee learning and development. PPD was named to Training magazine’s Top 100 list, which honors companies that demonstrate measurable results from effective employee learning and development tied to strategic goals.

“Earning this recognition for the 10th year in a row underscores PPD’s commitment to achieving effective training and employee development outcomes that provide tangible benefit to our customers and their drug-development initiatives,” said Jay Dixon, senior vice president of quality and enterprise learning at PPD. “Our learning culture contributes to making PPD a great company to work for and helps increase employee engagement and retention, enhancing continuity in our customers’ important research programs.”

“PPD’s learning strategy is directly linked with corporate objectives and is laser-focused to help its business achieve critical priorities,” said Lorri Freifeld, Training magazine’s editor-in-chief. “In the last year, the company initiated landmark project delivery upskilling initiatives to supercharge the performance of the thousands of its employees delivering clinical trials. PPD’s training leverages leading-edge technology, measurement methods and collaboration for optimum learner experience and engagement.”

This year marks a milestone for PPD as it is the highest ranking the company has received on Training magazine’s list. Training’s rankings are based on a variety of benchmarking statistics, such as total training budget; percentage of payroll; number of training hours per employee program; goals, evaluation, measurement and workplace surveys; hours of training per employee annually; and detailed formal programs.

Employee learning and development at PPD includes leadership and high-potential development, key talent programs, technical skills, job-specific training and individual contributor soft skills training, all of which are integrated and aligned with business goals and objectives. These initiatives are driven from the highest levels within PPD and supported by PPD’s global learning council, an enterprise-wide, cross-functional group of leaders working to ensure that PPD is a high-performing learning organization.

Rita Bragadesto, PPD principal learning specialist, also was named a 2020 Top 5 Emerging Training Leader by Training magazine. The honor recognizes training professionals who have been in the industry for two to 10 years and have demonstrated exceptional leadership skills, business savvy and training instincts. Bragadesto received her award at Training’s virtual ceremony on Feb. 8.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.

This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Media:
Nadine Maeser
+1 919 456 4425
media@ppd.com

Investors:
Tracy Krumme
+1 910 558 4186
investors@ppd.com